What's Happening?
Creatv Bio, a division of Creatv MicroTech, Inc., has inaugurated a new CLIA-certified laboratory in Monmouth Junction, New Jersey. This facility is designed to support the development and testing of oncology drugs by offering advanced diagnostic services.
The laboratory will utilize the LifeTracDx® Blood Test, which measures Cancer Associated Macrophage-Like cells (CAMLs) and Circulating Tumor Cells (CTCs). These tests are crucial for monitoring early treatment responses, improving patient selection, and developing companion diagnostics. The LifeTracDx® test is particularly significant as it allows for the real-time monitoring of drug target expression and resistance, as well as the measurement of PD-L1 expression for immunotherapy. Dr. Cha-Mei Tang, President and CEO of Creatv Bio, emphasized that this development marks a significant advancement in accelerating cancer drug development.
Why It's Important?
The opening of this laboratory is a pivotal development in the field of oncology drug development. By providing rapid and reliable analyses, Creatv Bio's facility can significantly enhance the efficiency of clinical trials. The ability to monitor treatment responses early and accurately can lead to more effective patient selection, potentially reducing the time and cost associated with drug development. This advancement is particularly important for pharmaceutical companies seeking to develop targeted therapies, as it allows for the co-development of drugs and diagnostics. The laboratory's capabilities could lead to more personalized treatment plans, improving outcomes for cancer patients and advancing the field of precision medicine.
What's Next?
With the new laboratory operational, Creatv Bio is poised to expand its partnerships with pharmaceutical companies engaged in oncology drug trials. The facility's capabilities may attract more biopharma companies looking to enhance their drug development processes. As the laboratory begins to deliver its services, it is likely to contribute to a faster and more efficient drug approval process. The focus on real-time monitoring and biomarker expression could lead to new insights into cancer treatment, potentially influencing future research and development strategies in the oncology sector.
